SCHOFIELD, Wis., Feb. 7, 2012 /PRNewswire/ -- PuraMed BioScience, Inc. (OTC QB: PMBS) announced today that it has recently commenced a clinical study of its unique non-prescription migraine treatment, LipiGesic®M on children and adolescents. Currently there are no prescription migraine medications recommended for those under the age of 18, and PuraMed hopes to attract that market with the results from this upcoming study.
“We are very excited to begin the clinical study of LipiGesic®M and its effectiveness on children, said PuraMed BioScience CEO, Russ Mitchell. Currently there is an estimated 2 million migraine sufferers under the age of 18, who cannot be recommended prescription treatment, and we believe this will be a significant market to capture. Due to our high efficacy rate and low side effect profile, we believe the results will demonstrate that LipiGesic®M is not only the best option for migraine relief amongst adults, but children as well.”
This multi-site, double blind placebo controlled study will be led by leading headache researcher, Dr. Roger Cady, who was also responsible for PuraMed’s previous clinical study which was published in the top-tier medical journal Headache. The study will include children ages 6-11 as well as adolescents ages 12-17 and will be conducted at key centers across the country.
About PuraMed BioScience, Inc.:
PuraMed BioScience, Inc. engages in the research, development and marketing of non-prescription medicinal and healthcare products. PuraMed has completed a double blind placebo clinical trial for its leading product, LipiGesic®M, a sublingual acute treatment for the relief from migraine headaches, which was published in the top-tier medical journal, Headache. Please see the following link to view the abstract of that study. http://onlinelibrary.wiley.com/doi/10.1111/j.1526-4610.2011.01910.x/abstract.
LipiGesic®M has national distribution and is available nationwide in some of the largest chain drug stores in the United States. In addition to LipiGesic®M, the Company also has plans to launch LipiGesic®H for tension-type headaches as well as LipiGesic®PM which provides a remedy for insomnia and other sleep disorders.
For more information on PuraMed, visit the Company website at www.PuraMedBioScience.com, and join the Company’s group page on Facebook by searching “PuraMed BioScience.”
Forward Looking Statements:
This news release contains forward-looking statements regarding PuraMed BioScience and its future business plans, which statements involve known and unknown risks and uncertainties. Such risks and uncertainties may cause actual results and future achievements of PuraMed BioScience to be materially different than those implied by these forward-looking statements. PuraMed BioScience has and undertakes no obligation to provide public updates and revisions to these forward-looking statements to reflect any changes in its expectations of future events.
Contact:
PuraMed BioScience, Inc.
Russell Mitchell, Chairman and CEO
715-359-6373
rmitchell@PuramedBioScience.com
www.PuramedBioScience.com
Investor Relations:
Investor Awareness, Inc.
Tony Schor or James Foy
847-945-2222
www.investorawareness.com
SOURCE PuraMed BioScience, Inc.
